Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients

Lamers, K.J.B.; Vos, Petra J.E.; Verbeek, Marcel M.; Rosmalen, F. M. A.; Geel, W.J.A. van; Engelen, B.G.M. van

doi:10.1016/s0361-9230(03)00089-3

Cited by 128 publications

(80 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Myelination of CNS>PNS Diagnosis [104] Infarct volume [103] Stroke severity [103] Inflammatory Biomarkers CRP Liver synthesis Acute phase reactant, role in atherotherombosis & ischemic injury [105] Diagnosis [106] Stroke risk [62,[107][108][109] IL-6 Cytokine from T-cells+ macrophages Acute phase response, fever Infarct volume [53][54][55]110] Stroke Severity [110] END [53,54] TNF-α Cytokine, inflammatory cells Inflammation, Acute phase response Infarct volume [53] Stroke Severity [53] END [72] VCAM 1 Immunoglobulin Leukocyte-endothelial cell interaction Diagnosis [19] Infarct volume [53] ICAM 1 Immunoglobulin Leukocyte-endothelial cell interaction…”

Section: Protein Biomarkers In Ischemic Strokementioning

confidence: 99%

Blood Biomarkers of Ischemic Stroke

2011

View full text Add to dashboard Cite

This review provides a summary of the protein and RNA biomarkers that have been studied for the diagnosis and assessment of ischemic stroke. Many of the biomarkers identified relate to the pathophysiology of ischemic stroke, including ischemia of CNS tissue, acute thrombosis and inflammatory response. These biomarkers are summarized by their intended clinical application in ischemic stroke including diagnosis, prediction of stroke severity and outcome, and stratification of patients for stroke therapy. Among the biomarkers discussed are recent whole genome studies using RNA expression profiles to diagnose ischemic stroke and stroke etiology. Though many candidate blood based biomarkers for ischemic stroke have been identified, none are currently used in clinical practice. With further well designed study and careful validation, the development of blood biomarkers to improve the care of patients with ischemic stroke may be achieved.

show abstract

Section: Protein Biomarkers In Ischemic Strokementioning

confidence: 99%

Blood Biomarkers of Ischemic Stroke

2011

View full text Add to dashboard Cite

show abstract

“…After stroke, leaking brain factors can be detected in the blood (S100B, neuron specific enolase, glial fibrillary acid protein, and myelin basic protein), although S100B and glial fibrillary acid protein are of low sensitivity for early stroke diagnosis and neuron specific enolase and myelin basic protein are nonspecific. 36,37 More recently, a panel of 4 soluble factors in the plasma-2 markers of inflammation (matrix metalloproteinase-9 and vascular cell adhesion molecule), 1 marker of glial activation (S100␤), and 1 thrombosis marker (von Willebrand factor)-demonstrated moderately high sensitivity and specificity for the diagnosis of stroke. 36 In this work, several gene lists obtained from a number of different MCC methods were generated because it is not yet known which is the most representative.…”

Section: Moore Et Al Gene Expression Profile Of Acute Stroke 217mentioning

confidence: 99%

“…36,37 More recently, a panel of 4 soluble factors in the plasma-2 markers of inflammation (matrix metalloproteinase-9 and vascular cell adhesion molecule), 1 marker of glial activation (S100␤), and 1 thrombosis marker (von Willebrand factor)-demonstrated moderately high sensitivity and specificity for the diagnosis of stroke. 36 In this work, several gene lists obtained from a number of different MCC methods were generated because it is not yet known which is the most representative. If we are too stringent, genes that may have a real biological effect could be removed, and if we are too liberal, too many falsepositives may be included.…”

Section: Moore Et Al Gene Expression Profile Of Acute Stroke 217mentioning

confidence: 99%

Using Peripheral Blood Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke

et al. 2005

View full text Add to dashboard Cite

Background-Direct brain biopsy is rarely indicated during acute stroke. This study uses peripheral blood mononuclear cells (PBMCs) to determine whether a systemic gene expression profile could be demonstrated in patients with acute ischemic stroke. Methods and Results-Using oligonucleotide microarrays, we compared the gene expression profile of an index cohort of 20 patients with confirmed ischemic stroke on neuroimaging studies with that of 20 referent subjects. Validation studies used quantitative real-time polymerase chain reaction to measure the levels of 9 upregulated genes in the index cohort, and an independent cohort of 9 patients and 10 referent subjects was prospectively studied to determine the accuracy of the Prediction Analysis for Microarrays list to classify stroke. After correction for multiple comparisons with the Bonferroni technique, 190 genes were significantly different between the stroke and referent groups. Broad classes of genes included white blood cell activation and differentiation (Ϸ60%), genes associated with hypoxia and vascular repair, and genes potentially associated with an altered cerebral microenvironment. Real-time polymerase chain reaction confirmed increased mRNA expression in 9 of 9 upregulated stroke-associated genes in the index cohort. A panel of 22 genes derived from the Prediction Analysis for Microarrays algorithm in the index cohort classified stroke in the validation cohort with a sensitivity of 78% and a specificity of 80%.

show abstract

“…Moreover, protein S-100B, neuron-specific enolase, myelin basic protein and glial fibrillary acidic protein in CSF and blood of patients with an acute or chronic progressive neurological disorder with brain damage are important indicators for medical practitioners. Particularly in disorders with acute brain damage, determination of the aforementioned proteins in CSF and blood can be helpful to establish structural and/or functional brain damage to determine severity and prognosis of the disease process and to monitor treatment effects [9].…”

Section: Introductionmentioning

confidence: 99%

Real-Time Monitoring of Bodily Fluids Using a Novel Electromagnetic Wave Sensor

Mason

Goh

Korostynska³

et al. 2013

PHF

View full text Add to dashboard Cite

Abstract-The use of a novel low power electromagnetic sensor for real-time detection of lactate in cerebrospinal fluid (CSF) is investigated. CSF holds key indicators relating to a patient's future health. A multipurpose sensor platform is currently being developed with the capability to detect the concentration of materials in volumes ≤1 ml. This paper presents results from a microwave cavity resonator designed and created for this purpose, using varying concentrations of lactate in water. The work demonstrates the feasibility of monitoring bodily fluids in real-time. Such advancements are essential for improved and cost-effective delivery of healthcare services to patients.

show abstract

Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients

Cited by 128 publications

References 27 publications

Blood Biomarkers of Ischemic Stroke

Blood Biomarkers of Ischemic Stroke

Using Peripheral Blood Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke

Real-Time Monitoring of Bodily Fluids Using a Novel Electromagnetic Wave Sensor

Contact Info

Product

Resources

About